CTLA4 and melanoma: In 2011, ipilimumab, a human monoclonal cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, was the first immune checkpoint inhibitor (ICI) approved for use in patients with metastatic or unresectable melanoma [2].